Heron Therapeutics is a deeply distressed but potentially asymmetric biotech turnaround, where ZYNRELEF’s reimbursement-driven acute-care ramp must outrun CINVANTI generic erosion, debt pressure, and Nasdaq delisting risk.
Overview
Heron Therapeutics is a U.S.-focused commercial-stage biotech with four FDA-approved products across acute care and oncology supportive care. Its investment story centers on whether ZYNRELEF and APONVIE can scale fast enough to offset erosion in CINVANTI and SUSTOL. ZYNRELEF offers differentiated 72-hour non-opioid post-surgical analgesia, while APONVIE and CINVANTI provide rapid IV-push aprepitant formulations. The products are clinically differentiated, but the company faces high debt, legal overhangs, weak profitability, and a speculative transition profile.